Abstract:BACKGROUND:Despite recent reforms, distorting funding mechanisms and over-prescribing still maintain severe financial barriers to medicines access in China. Complicated and interrelated problems in the pharmaceutical sector require a common framework to be resolved as fragmented solutions do not work. We present a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and propose policy recommendations for promoting universal access to medicines in China.METHODS:Drawing on multiple sources of information, including a review of published literatures and official national data, field investigations in six provinces and interviews with key opinion leaders, this paper presents a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and proposes policy recommendations for promoting universal access to medicines in China.RESULTS:Public expenditure on medicines has been strictly controlled since the national healthcare reforms of 2009. Yet total pharmaceutical expenditure (TPE) and total health expenditure growth rates continuously outpaced the growth of gross domestic product (GDP). With 2.4% of GDP, TPE now exceeds that of most high income countries. The distorted provider and consumer incentives in the Chinese health system have not fundamentally changed. Price-setting and reimbursement mechanisms do not promote cost-effective use of medicines. Inappropriate price controls and perverse financial incentives are the un-resolved root causes of preference of originator brands for some major diseases and shortages of low-cost and low-consumption medicines. In addition, access to expensive life-saving medicines is yet systematically addressed.CONCLUSIONS:The complicated and interdependent problems interact in a way that leads to significant system problems in China, which create dual challenges that both the developing country and the developed countries are facing. To further promote access to medicines, China should speed up the re-assessment of the quality and efficacy of domestically produced generic medicines; coordinate various reforms of price determination, insurance payments, and procurement policies; address medicine shortages through comprehensive policies and legislation; establish specific mechanisms to achieve sustainable equitable access to expensive essential medicines with health technology assessment as a tool to ensure that policy and priority setting are created in a coherent and evidence-based way.

Present Situation and Thinking of Pharmaceutical Distribution System in China

Problems and Reform Strategies of Medicines Distribution System in China

Investigation on the Issues about Distribution of National Essential Drug

Causes of the unduly rapid growth of drug expenses in China and countermeasures

Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts

Concepts for the Construction of a New National Drug Service System

A Review of Promoting Access to Medicines in China - Problems and Recommendations.

Analysis and Suggestions on current situation of Chinese Drug Shortage Problem

Issues in Drug Pricing,Reimbursement and Access in China from the International Perspectives

Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.

A brief analysis of favorable and unfavorable conditions for future development of pharmaceutical E-commerce in China

Zero mark-up policy of essential medicines system in China:Problems and recommendations

Studv on the Current Situation of Allocation and Utilization of Major Medical Equipment in China and Relevant Policy Suggestions

The Current Status and Development Countermeasures of Online Pharmacies in China

Reform of the Essential Drugs Supply Mode in One District,shanghai

Investigation on"Two Tax Bill"Medicines Distribution Reform

Influence of “Separated Management between Medicine and Pharmacy” on Hospital Pharmaceutical Affairs Management in Beijing

Analysis and discussion on the pharmaceutical centralized procurement implementation — a case study of a large provincial hospital in China

Analysis of the problems of drug sampling and testing programme under tripartite system reform in China

Analysis of the Driving Force in the Separation of Pharmacy and Medicine

Survey of Status Quo of Hospital Pharmaceutical Services and Clinical Pharmacy in China (Part 1): General Situation of Hospital Pharmaceutical Services